Akebia Therapeutics (AKBA) PT Raised to $18 at Needham & Company
Tweet
Share
E-mailGet Alerts AKBA Hot Sheet
Price: $1.24 --0%
Rating Summary:
13 Buy, 5 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 12 | Down: 22 | New: 24
Rating Summary:
13 Buy, 5 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 12 | Down: 22 | New: 24
Join SI Premium – FREE
Needham & Company analyst Chad Messer raised the price target on Akebia Therapeutics (NASDAQ: AKBA) to $18.00 (from $15.00) while maintaining a Buy rating.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Barclays Upgrades Lincoln National (LNC) to Overweight
- Kepler Cheuvreux Downgrades Continental AG (CON:GR) (CTTAY) to Hold
- Koninklijke Ahold Delhaize NV (AD:NA) (ADRNY) PT Lowered to EUR38 at UBS
Create E-mail Alert Related Categories
Analyst PT ChangeRelated Entities
Needham & CompanySign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
